» Articles » PMID: 24062746

Central Role of the Gut Epithelial Barrier in the Pathogenesis of Chronic Intestinal Inflammation: Lessons Learned from Animal Models and Human Genetics

Overview
Journal Front Immunol
Date 2013 Sep 25
PMID 24062746
Citations 204
Authors
Affiliations
Soon will be listed here.
Abstract

The gut mucosa is constantly challenged by a bombardment of foreign antigens and environmental microorganisms. As such, the precise regulation of the intestinal barrier allows the maintenance of mucosal immune homeostasis and prevents the onset of uncontrolled inflammation. In support of this concept, emerging evidence points to defects in components of the epithelial barrier as etiologic factors in the pathogenesis of inflammatory bowel diseases (IBDs). In fact, the integrity of the intestinal barrier relies on different elements, including robust innate immune responses, epithelial paracellular permeability, epithelial cell integrity, as well as the production of mucus. The purpose of this review is to systematically evaluate how alterations in the aforementioned epithelial components can lead to the disruption of intestinal immune homeostasis, and subsequent inflammation. In this regard, the wealth of data from mouse models of intestinal inflammation and human genetics are pivotal in understanding pathogenic pathways, for example, that are initiated from the specific loss of function of a single protein leading to the onset of intestinal disease. On the other hand, several recently proposed therapeutic approaches to treat human IBD are targeted at enhancing different elements of gut barrier function, further supporting a primary role of the epithelium in the pathogenesis of chronic intestinal inflammation and emphasizing the importance of maintaining a healthy and effective intestinal barrier.

Citing Articles

A novel two-component system contributing the catabolism of c-di-GMP influences virulence in .

Liu C, Shao J, Ma X, Tang Y, Li J, Li H Front Microbiol. 2025; 16:1527317.

PMID: 39980697 PMC: 11841396. DOI: 10.3389/fmicb.2025.1527317.


Early fecal microbiota transplantation continuously improves chicken growth performance by inhibiting age-related Lactobacillus decline in jejunum.

Liu Q, Akhtar M, Kong N, Zhang R, Liang Y, Gu Y Microbiome. 2025; 13(1):49.

PMID: 39930537 PMC: 11808950. DOI: 10.1186/s40168-024-02021-6.


Microbiome-derived metabolite effects on intestinal barrier integrity and immune cell response to infection.

Adams L, Li X, Burchmore R, Goodwin R, Wall D Microbiology (Reading). 2024; 170(10).

PMID: 39392674 PMC: 11469068. DOI: 10.1099/mic.0.001504.


Regulatory effects of the p38 mitogen-activated protein kinase-myosin light chain kinase pathway on the intestinal epithelial mechanical barrier and the mechanism of modified Pulsatilla decoction in the treatment of ulcerative colitis.

Tingting W, Xin Y, Huiping Z, Jinwei G, Hui Z, Peipei Z J Tradit Chin Med. 2024; 44(5):885-895.

PMID: 39380219 PMC: 11462527. DOI: 10.19852/j.cnki.jtcm.20240806.006.


Evaluating the Impact of the PoultryStarBro Probiotic on the Incidence of Bacterial Chondronecrosis with Osteomyelitis Using the Aerosol Transmission Challenge Model.

Perera R, Alharbi K, Hasan A, Asnayanti A, Do A, Shwani A Microorganisms. 2024; 12(8).

PMID: 39203472 PMC: 11356867. DOI: 10.3390/microorganisms12081630.


References
1.
Garrison W, Battle M, Yang C, Kaestner K, Sladek F, Duncan S . Hepatocyte nuclear factor 4alpha is essential for embryonic development of the mouse colon. Gastroenterology. 2006; 130(4):1207-20. PMC: 3581272. DOI: 10.1053/j.gastro.2006.01.003. View

2.
Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L . An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003; 4(7):702-7. DOI: 10.1038/ni945. View

3.
Farmer M, Sundberg J, Bristol I, Churchill G, Li R, Elson C . A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci U S A. 2001; 98(24):13820-5. PMC: 61125. DOI: 10.1073/pnas.241258698. View

4.
Weinberg E . Human lactoferrin: a novel therapeutic with broad spectrum potential. J Pharm Pharmacol. 2001; 53(10):1303-10. DOI: 10.1211/0022357011777792. View

5.
McGovern D, Taylor K, Landers C, Derkowski C, Dutridge D, Dubinsky M . MAGI2 genetic variation and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 15(1):75-83. PMC: 2614310. DOI: 10.1002/ibd.20611. View